The present invention relates to bioconjugates and labeled derivatives of the adducts formed by the reaction of patulin with benzene-1,2-dithiols or their salts. Said conjugates are suitable for the production of antibodies capable of recognizing the aforementioned patulin-(benzene-1,2-dithiols) adducts with high affinity and specificity. Likewise, the present invention also relates to the use of bioconjugates of patulin-(benzene-1,2-dithiols) adducts and of labeled derivatives thereof as assay antigens. Furthermore, the present invention also relates to immunochemical methods for the analysis of patulin, using the bioconjugates and labeled derivatives and antibodies of the invention, which include a previous step to quantitatively convert patulin into these adducts. This invention also provides a kit for analyzing patulin comprising a benzene-1,2-dithiol or its salts, antibodies against patulin-(benzene-1,2-dithiols) adducts, and assay antigens.

The present disclosure describes a unique viral peptide (VP) vaccine for preventing or treating viral diseases. The vaccine is produced synthetically and includes no production steps in biological cells (e.g. E. coli, CHO cells, yeast cells) that would require subsequent endotoxin assays/removal or viral clearance procedures. The hC peptide is synthesized separately from the VP, and following self-assembly of the hC, the VP is covalently coupled to form the VP-hC conjugate which can serve as a vaccine for preventing or treating viral diseases. The hC includes heptad repeats following a specific pattern. Optionally, the VP-hC conjugate further includes one or more T-cell epitopes at the N- and/or C-terminus of the one or more amphipathic alpha-helices. The present disclosure also describes compositions comprising immunogenic compositions including VP-hC conjugate.

The present invention relates, in part, to methods and compositions for enhancing anti-tumor immune responses. Particularly, the invention provides methods for enhancing the immune functions of Fc receptor (FcR)-expressing cells including dendritic cells, natural killer cells, macrophages, neutrophils, and eosinophils.

The present invention relates to vaccine compositions for treatment of substance use disorders, methods for the manufacture thereof, and methods for the use thereof to treat an animal. These compositions comprise a hapten conjugated via a linker to a protein scaffold and mixed with a particulate carrier and at least one immunostimulatory adjuvant molecule.

The present invention relates to vaccine compositions for treatment of substance use disorders, methods for the manufacture thereof, and methods for the use thereof to treat an animal. These compositions comprise a hapten conjugated via a linker to a protein scaffold and mixed with a particulate carrier and at least one immunostimulatory adjuvant molecule.

The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a tumor-associated antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the treatment of a tumor or in the treatment or prevention of a tumor relapse, and in the manufacture of medicaments therefore.

Advanced therapy medicinal products (AMTPs) for cell therapy. In particular, a composition including stressed HT-29, HCT-116 and LoVo cells, and immunogenic stress proteins produced by these cells in response to stresses applied in vitro. The composition allows to simultaneously counteract multiple cell resistance mechanisms observed in situ in cancer cells, and is therefore suitable for vaccinating and treating cancers in human patients.

The invention provides haptens and methods of preparation thereof, for producing immunoconjugates of oxycodone and hydrocodone suitable for raising antibodies in animals specific for the opioid drugs. Administration of the opioid-speeific antibodies to humans having the opioid drugs in a body fluid such as blood serum, binds the opioid drugs to the antibody, making the opioids unavailable for producing a drug effect. Accordingly the antibodies can be used to reverse the effects of a drug overdose of oxycodone and hydrocodone, or to reverse a perceived mental effect of the drugs, such as euphoria.

Disclosed is an isolated antibody or an antigen-binding fragment thereof The antibody is capable of binding to a muramyl peptide, or a derivative or an analog or a salt thereof. The muramyl peptide comprises muramic acid and an amino acid selected from the group consisting of alanine, isoglutamine, glutamic acid, and a salt thereof. Also disclosed are methods of producing the antibody, compositions comprising the antibody, methods of treating using the antibody, uses of the antibody, methods of detecting muramyl peptide, an assay for detecting muramyl peptide, an antibacterial agent, hybridomas and kits.

In some embodiments. methods of treating cervical cancer, including cervical cancers that are resistant to immune checkpoint inhibitor therapy. and cervical cancers that do not respond to immune checkpoint inhibitor therapy or have acquired resistance to immune checkpoint inhibitor therapy are disclosed.